Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPreferred Shares IssuedReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repaymentsWages, Salaries and Other
Ratios

Mangoceuticals (MGRX) Receivables - Other (2025)

Mangoceuticals' Receivables - Other history spans 1 years, with the latest figure at $20056.0 for Q4 2025.

  • On a quarterly basis, Receivables - Other changed N/A to $20056.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $20056.0, a N/A change, with the full-year FY2025 number at $20056.0, changed N/A from a year prior.
  • Receivables - Other hit $20056.0 in Q4 2025 for Mangoceuticals.
  • Over the last five years, Receivables - Other for MGRX hit a ceiling of $20056.0 in Q4 2025 and a floor of $20056.0 in Q4 2025.